Related Experiment Video

Updated: Jun 2, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

Feng Yang1, Chen Jin, Yong-jian Jiang

  • 1Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, 12 Central Urumqi Road, Shanghai Medical College, Fudan University, Shanghai 200040, China.

Expert Review of Anticancer Therapy
|April 21, 2011
PubMed

Insights

Soluble VEGF receptor-1 (sFlt-1) shows potential in antiangiogenesis cancer therapy, possibly mitigating toxicities like hypertension and proteinuria. Further research is needed to explore its therapeutic impact and role as a biomarker in cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Antiangiogenesis therapy is a promising cancer treatment, but assessing its efficacy and toxicity remains challenging.
  • Soluble VEGF receptor-1 (sFlt-1) is implicated in preeclampsia, sharing toxicities with antiangiogenesis treatments.
  • Intratumoral sFlt-1 and VEGF levels correlate with tumor malignancy, patient survival, and therapy response.

Purpose of the Study:

  • To investigate the role of sFlt-1 in antiangiogenesis therapy for cancer.
  • To explore sFlt-1's potential as a therapeutic agent and biomarker for treatment response and toxicity.

Main Methods:

  • Review of clinical evidence and animal studies on sFlt-1 and anti-VEGF agents.
  • Analysis of the correlation between intratumoral sFlt-1/VEGF levels and cancer characteristics.
  • Examination of changes in circulating angiogenic factors during antiangiogenesis therapy.

Main Results:

  • sFlt-1 may contribute to hypertension and proteinuria in patients receiving anti-VEGF therapy.
  • Preclinical studies validate sFlt-1's therapeutic potential as an antiangiogenic agent.
  • Antiangiogenesis therapy alters circulating levels of VEGF, sFlt-1, and other VEGFRs, suggesting biomarker potential.

Conclusions:

  • sFlt-1 holds promise for developing novel molecular therapeutics in oncology.
  • Understanding sFlt-1's impact is crucial for advancing antiangiogenesis cancer therapy.
  • Circulating angiogenic factors may serve as biomarkers for antiangiogenesis therapy efficacy and toxicity.

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...